Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down by more than 55% just a few ...
Idera Pharmaceuticals’ TLR9 agonist has failed to improve on Yervoy in a phase 3 melanoma trial. The miss on the objective response rate endpoint sent shares in Idera down 55%, but the biotech is yet ...
Partners Group has taken a controlling stake in Idera in a transaction that values the business-to-business software company at close to $3 billion, sources familiar with the deal’s terms told PE Hub.
Partners Group acquired a minority stake in Idera, a business-to-business software company backed by TA Associates, HGGC and the company’s management. The PE firm joins current investors with a 25 ...
CAMBRIDGE, Mass. and EXTON, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Idera Pharmaceuticals' stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene . Idera's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results